BioCentury | Sep 12, 2011
Politics, Policy & Law

Biodefense report card

Ten years after 9/11 and the subsequent anthrax attacks alerted America to the threat posed by bioterrorism, progress in developing and procuring vaccines and drugs to protect the civilian population has been frustratingly slow. An...
BC Week In Review | Aug 2, 2010
Company News

diaDexus, VaxGen deal

The companies completed their previously announced merger. diaDexus LLC will operate as a subsidiary of VaxGen (see BioCentury, June 7). diaDexus Inc. , South San Francisco, Calif.   VaxGen Inc. (OTCBB:VXGN), South San Francisco, Calif.  ...
BC Week In Review | Jun 7, 2010
Company News

diaDexus, VaxGen deal

The companies amended their previously announced merger. VaxGen will now own about 62% of the combined company, up from 39.1%, while diaDexus shareholders will own 38%, down from 60.9%. The move comes after diaDexus temporarily...
BC Week In Review | Apr 19, 2010
Company News

diaDexus, VaxGen deal

Diagnostic company diaDexus will reverse-merge with VaxGen in a stock deal. diaDexus shareholders will own 60.9% of the combined company, which will be known as diaDexus Inc., with VaxGen shareholders owning the remaining 39.1%. The...
BioCentury | Apr 19, 2010
Finance

Public at last

diaDexus Inc. was founded in 1997 as a 50-50 joint venture between SmithKline Beecham and Incyte Pharmaceuticals Inc. (now Incyte Corp. (NASDAQ:INCY)) to commercialize molecular diagnostics. It's one of the first companies formed with the...
BC Extra | Apr 16, 2010
Company News

diaDexus, VaxGen to reverse-merge

Diagnostic company diaDexus Inc. (South San Francisco, Calif.) will reverse-merge with VaxGen Inc. (OTCBB:VXGN) in a stock deal. diaDexus shareholders will own 60.9% of the combined company, which will be known as diaDexus, with VaxGen...
BioCentury | Apr 5, 2010
Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date 12-mo op loss ended 12/31/09 1/7/10 Molecular Insight Pharmaceuticals Inc. (NASDAQ:MIPI) 13% to 61 $64.0 1.38 12/31/09 $46.3 Cuts are companywide; expects annual...
BC Week In Review | Feb 15, 2010
Company News

OxiGene, VaxGen deal

OxiGene's planned acquisition of VaxGen for about $22.2 million stock will not take place after a majority of VaxGen's shareholders did not approve the deal. At the Feb. 3 meeting of shareholders, 13.2 million shares...
BC Week In Review | Oct 26, 2009
Clinical News

ALVAC HIV vaccine: Additional Phase III data

Additional data from the U.S. Army Surgeon General-sponsored, double-blind, Thai Phase III RV144 trial in 16,402 adult volunteers showed that Sanofi Pasteur S.A.'s ALVAC HIV vaccine boosted by the AIDSVAX B/E gp120 vaccine missed the...
BioCentury | Oct 26, 2009
Finance

Ebb & Flow

Despite the brutal fundraising environment, New Enterprise Associates is close to wrapping up its 13th fund. According to an SEC filing, the firm has raised $2.46 billion of a planned $2.5 billion, which would put...
Items per page:
1 - 10 of 238
BioCentury | Sep 12, 2011
Politics, Policy & Law

Biodefense report card

Ten years after 9/11 and the subsequent anthrax attacks alerted America to the threat posed by bioterrorism, progress in developing and procuring vaccines and drugs to protect the civilian population has been frustratingly slow. An...
BC Week In Review | Aug 2, 2010
Company News

diaDexus, VaxGen deal

The companies completed their previously announced merger. diaDexus LLC will operate as a subsidiary of VaxGen (see BioCentury, June 7). diaDexus Inc. , South San Francisco, Calif.   VaxGen Inc. (OTCBB:VXGN), South San Francisco, Calif.  ...
BC Week In Review | Jun 7, 2010
Company News

diaDexus, VaxGen deal

The companies amended their previously announced merger. VaxGen will now own about 62% of the combined company, up from 39.1%, while diaDexus shareholders will own 38%, down from 60.9%. The move comes after diaDexus temporarily...
BC Week In Review | Apr 19, 2010
Company News

diaDexus, VaxGen deal

Diagnostic company diaDexus will reverse-merge with VaxGen in a stock deal. diaDexus shareholders will own 60.9% of the combined company, which will be known as diaDexus Inc., with VaxGen shareholders owning the remaining 39.1%. The...
BioCentury | Apr 19, 2010
Finance

Public at last

diaDexus Inc. was founded in 1997 as a 50-50 joint venture between SmithKline Beecham and Incyte Pharmaceuticals Inc. (now Incyte Corp. (NASDAQ:INCY)) to commercialize molecular diagnostics. It's one of the first companies formed with the...
BC Extra | Apr 16, 2010
Company News

diaDexus, VaxGen to reverse-merge

Diagnostic company diaDexus Inc. (South San Francisco, Calif.) will reverse-merge with VaxGen Inc. (OTCBB:VXGN) in a stock deal. diaDexus shareholders will own 60.9% of the combined company, which will be known as diaDexus, with VaxGen...
BioCentury | Apr 5, 2010
Finance

Restructuring Watch

Restructuring Watch Date Company Staff cuts Cash Years cash pre-cut Cash date 12-mo op loss ended 12/31/09 1/7/10 Molecular Insight Pharmaceuticals Inc. (NASDAQ:MIPI) 13% to 61 $64.0 1.38 12/31/09 $46.3 Cuts are companywide; expects annual...
BC Week In Review | Feb 15, 2010
Company News

OxiGene, VaxGen deal

OxiGene's planned acquisition of VaxGen for about $22.2 million stock will not take place after a majority of VaxGen's shareholders did not approve the deal. At the Feb. 3 meeting of shareholders, 13.2 million shares...
BC Week In Review | Oct 26, 2009
Clinical News

ALVAC HIV vaccine: Additional Phase III data

Additional data from the U.S. Army Surgeon General-sponsored, double-blind, Thai Phase III RV144 trial in 16,402 adult volunteers showed that Sanofi Pasteur S.A.'s ALVAC HIV vaccine boosted by the AIDSVAX B/E gp120 vaccine missed the...
BioCentury | Oct 26, 2009
Finance

Ebb & Flow

Despite the brutal fundraising environment, New Enterprise Associates is close to wrapping up its 13th fund. According to an SEC filing, the firm has raised $2.46 billion of a planned $2.5 billion, which would put...
Items per page:
1 - 10 of 238